1H NMR serum metabolomic profiling of patients at risk of cardiovascular diseases performing stress test

Camila Lema1, Mireia Andrés1, Santiago Aguadé-Bruix1, Marta Consegal1,2, Antonio Rodriguez-Sinovas1,2, Begoña Benito1,2, Ignacio Ferreira-Gonzalez1,3* & Ignasi Barba1,2,4*

Cardiovascular diseases are the leading cause of death worldwide1, being coronary artery disease (CAD) one of the most prevalent cardiovascular disorders. Changes in lifestyle and/or pharmacological treatment are able to reduce the burden of CAD and early diagnosis is crucial for a timely and optimal management of the disease. Stress testing is a good method to measure the burden of CAD but it is time consuming and pharmacological testing may not fully mimic exercise test. The objectives of the present project were to characterize the metabolic profile of the population undergoing pharmacological and exercise stress testing to evaluate possible differences between them, and to assess the capacity of 1H NMR spectroscopy to predict positive stress testing. Pattern recognition was applied to 1H NMR spectra from serum of patients undergoing stress test and metabolites were quantified. The effects of the stress test, confounding variables and the ability to predict ischemia were evaluated using OPLS-DA. There was an increase in lactate and alanine concentrations in post-test samples in patients undergoing exercise test, but not in those submitted to pharmacological testing. However, when considering only pharmacological patients, those with a positive test result, showed increased serum lactate, that was masked by the much larger amount of lactate associated to exercise testing. In conclusion, we have established that pharmacological stress test does not reproduce the dynamic changes observed in exercise stress. Although there is promising evidence suggesting that 1H NMR based metabolomics could predict stress test results, further studies with much larger populations will be required in order to obtain a definitive answer.

Cardiovascular diseases are the leading cause of death worldwide1, being coronary artery disease (CAD) one of the most prevalent cardiovascular disorders. Changes in lifestyle and/or pharmacological treatment are able to reduce the burden of CAD, so early diagnosis becomes crucial for a timely and optimal management of the disease2. At present, the risk of CAD can be evaluated by the presence of established risk factors (including age, sex, hypertension, hypercholesterolemia, obesity, diabetes mellitus, sedentary lifestyle and smoking) in tables such as the Framingham Risk Score and the Adult Treatment Panel III, SCORE (Systematic Coronary Risk Evaluation)3,4. In patients at risk of CAD, confirmation of the disease is established by invasive coronary angiography, and more recently, by angio-coronary computed tomography (CT) scan, showing obstructive plaques at the coronary lumen. These two techniques, considered the gold-standard diagnostic tools for CAD, are however limited by their risks (particularly those inherent to an invasive procedure in the case of coronary angiogram), radiation exposure, and costs. Other cardiac noninvasive techniques such as stress echocardiography, cardiac magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT)5,6 have been used to predict (with moderate ability) the presence of CAD. While nuclear stress testing has sensitivity above 80% and specificity that reaches 95%7, it is also time consuming and not adequate for population screening.
Furthermore, it is not clear if pharmacological stress applied to the patients that cannot exercise has the same clinical interpretation as exercise testing.

There is considerable interest in developing personalized, non-invasive methods for cardiovascular risk stratification that could be applied at the population level. Metabolomics has the potential to play a leading role in the development of personalized medicine. In recent years there has been an effort to develop novel strategies based on ¹H NMR profiling of serum for the personalized diagnosis and prognosis of CAD. However, the results have been of limited value and the approach has not yet reached clinical practice.

Low-molecular-weight metabolites are relevant to exercise physiology and myocardial ischemia, and therefore studies with different approaches have been carried out to develop or improve current tools for risk stratification of patients with suspected CAD. Sabatine et al. showed that metabolites such as lactate and alanine, and particularly compounds related to the citric acid pathway, are increased in the setting of myocardial ischemia. Using a ¹H NMR-based approach in patients undergoing stress test, our group described that the main contributors to discriminate between ischemia (post-exercise) and baseline (pre-exercise) samples were lactate, glucose, methyl and methylene moieties of lipids and long-chain amino acids (valine, leucine, and isoleucine). More recently, a study conducted in the emergency department showed that acylcarnitines were associated with increased acute coronary syndrome risk.

The objectives of the present project were two fold; first, we evaluated the metabolic profile and dynamics over time of patients undergoing a pharmacological stress test compared to those undergoing exercise stress test on a treadmill; secondly, we evaluated the capacity of ¹H NMR spectroscopy to predict positive testing in both modalities of stress (pharmacological and exercise).

Results

Epidemiological and clinical characteristics of the patients. Of 244 consecutive patients referred for exercise or pharmacological test, 32 were excluded because of insufficient exercise and need to complete the test with pharmacological stress (mixed stress test). Of the 212 eligible patients, 83 underwent a pharmacological test and 86 underwent an exercise test. Out of the patients undergoing pharmacological test, 20 had a positive result (cases), and 23 age- and sex-matched controls (with negative result) were selected. Among patients undergoing exercise test, 39 were positive (cases) and 44 age- and sex-matched controls were selected.

Table 1 summarizes the epidemiological and clinical characteristics of the overall population, as well as the results of the stress tests. Most patients were men (76.2%), and the mean age was 67.2 ± 10.7 years. The prevalence of cardiovascular risk factors was high, with more than 65% of patients being current or former smokers, almost 70% having hypertension, more than 80% having dyslipidemia and one third being diabetic. Up to 50% of patients had a history of previous CAD, in 82% of cases with previous coronary revascularization.

Table 1 also presents the characteristics of patients according to the two stress protocols. Women were more prevalent in the pharmacological group (46.5% vs 12.0% in the exercise stress group; P < 0.001). As expected, patients who performed a pharmacological stress test, compared to those who underwent an exercise test, were significantly older (73.7 ± 8.8 vs. 63.8 ± 10.2 years; P < 0.001), and had more comorbidities such as chronic kidney disease, higher body mass index (BMI) and a trend to higher prevalence of hypertension and diabetes.

¹H NMR Spectrum characterization. Figure 1 shows the typical spectra of a whole serum sample obtained with different pulse sequences. The use of different pulse sequences allows to investigate different properties of the samples; spectra obtained with pulse-and-acquire (Fig. 1A) is dominated by large broad peaks corresponding to the methyl groups of lipids in lipoprotein centered at 0.9 ppm; a large peak of methylene protons at 1.28 ppm; a doublet corresponding to lactate at 1.35 ppm; and various peaks of glucose in the area between 3.2 and 3.9 ppm. The CPMG sequence (Fig. 1B) is T2-edited and removes the signal from large, slow tumbling, macromolecules. Thus, low molecular weight metabolites such as lactate, glucose and aminoacids at around 1 ppm are easier to detect. Finally, signals from low molecular weight metabolites are removed from the diffusion-edited spectra (Fig. 1C) and only the signals arising from the lipoprotein envelope remain.

The effect of confounding variables. Visual inspection of the spectra did not allow identifying any major characteristics associated with the potential confounding factors including age, sex, dyslipidemia, DM or pharmacological treatment, particularly the use of statins. PCA, an unsupervised pattern recognition approach, did not show any clustering associated with the confounding variables.

When applying supervised discriminant analysis (OPLS-DA), it was possible to discriminate between men and women using the spectra acquired with different pulse sequences (Characteristics of the different discriminant models are detailed in Table 2). Classification success was between 92 and 96% depending on the spectra. The main differences were found around the lipid area (1.28 and 0.9 ppm). Figure 2 corresponds to the OPLS-DA model (A) discriminating men from women. The most relevant variables of discrimination were found in the lipid region (Fig. 2B,C), and showed that it was the shape of the peaks, rather than their intensity, that was associated with sex discrimination, as women lipid peaks tended to shift to lower field (higher ppm values).

Table 2 shows the characteristics of the discriminant models to differentiate between men and women obtained with different pulse-sequence spectra. Although deproteinized spectra were also able to differentiate between men and women (Table 2, NOESYPR1D), metabolite quantification obtained from the same spectra (Table 3) showed no differences in metabolite quantification once corrected for multiple comparisons.

Patients with diabetes mellitus could not be differentiated from controls by discriminant analysis in any of the spectra. However, it is worth noting that most diabetic patients were taking oral antidiabetic agents and no one showed a glucose level above 6 mmol/L at the time of analysis. Similarly, patients with dyslipidemia (most of them treated with statins) could not be discriminated. However, statin treatment induced a reduction in the
height of the methylene lipid peaks –(CH\textsubscript{2})\textsubscript{n} at around 1.28 ppm and at around 2.0 ppm, the area were lipid double bonds appear, that could be detected in pulse-and-acquire and diffusion-edited spectra (Supplementary Fig. 1). However, the effect was lost in deproteinized and T2-edited spectra. Finally, we could not detect differences in the concentrations of low molecular weight metabolites associated with dyslipidemia or statin treatment (Supplementary Table 2).

| Characteristics          | Total (N = 126) | Exercise stress test (N = 83) | Pharmacological stress test (N = 43) | P     |
|--------------------------|----------------|------------------------------|--------------------------------------|-------|
| Demographics             |                |                              |                                      |       |
| Sex, men                 | 96 (76.2%)     | 73 (88.0%)                   | 23 (53.5%)                           | <0.01 |
| Age (years)*             | 67.2 ± 10.7    | 63.8 ± 10.2                  | 73.7 ± 8.8                           | <0.01 |
| Cardiovascular risk factors |            |                              |                                      |       |
| Smoking                  | (n = 110)      | (n = 73)                     | (n = 37)                             | 0.09  |
| Ex smoker                | 62 (56.4%)     | 46 (63.0%)                   | 16 (43.2%)                           |       |
| Smoker                   | 12 (10.9%)     | 8 (11.0%)                    | 4 (10.8%)                            |       |
| Non smoker               | 36 (32.7%)     | 19 (26.0%)                   | 17 (45.9%)                           |       |
| Hypertension             | 87 (69.0%)     | 52 (62.7%)                   | 35 (81.4%)                           | 0.06  |
| Dyslipidemia             | 106 (84.1%)    | 72 (86.7%)                   | 34 (79.1%)                           | 0.20  |
| Diabetes mellitus        | 42 (33.3%)     | 23 (27.7%)                   | 19 (44.2%)                           | 0.08  |
| Non insulin requirement  | 26 (61.9%)     | 16 (19.3%)                   | 10 (23.3%)                           |       |
| Insulin requirement      | 16 (38.1%)     | 7 (8.4%)                     | 9 (20.9%)                            |       |
| Prior cardiovascular disease |                |                              |                                      |       |
| CAD                      | 63 (50.0%)     | 45 (54.2%)                   | 18 (41.9%)                           | 0.26  |
| Coronary revascularization | 52 (82.5%)     | 40 (88.8%)                   | 12 (66.7%)                           | 0.12  |
| Cerebrovascular disease  | 7 (5.6%)       | 3 (3.6%)                     | 4 (9.3%)                             | 0.23  |
| Chronic kidney disease   | 23 (18.2%)     | 6 (7.2%)                     | 17 (39.5%)                           | <0.01 |
| Pneumopathy              | 22 (17.5%)     | 12 (14.4%)                   | 10 (23.3%)                           | 0.34  |
| Long-term medication     |                |                              |                                      |       |
| Statins                  | 96 (76.2%)     | 65 (78.3%)                   | 31 (72.1%)                           | 0.37  |
| Fibrates                 | 5 (4.0%)       | 3 (3.6%)                     | 2 (4.7%)                             | 0.77  |
| Ezetimib                 | 9 (7.1%)       | 4 (4.8%)                     | 5 (11.6%)                            | 0.16  |
| ASA                      | 88 (69.8%)     | 64 (77.1%)                   | 24 (55.8%)                           | 0.01  |
| Beta-blockers            | 72 (57.1%)     | 46 (55.4%)                   | 26 (60.5%)                           | 0.71  |
| Nitrates                 | 27 (21.4%)     | 16 (19.3%)                   | 11 (25.6%)                           | 0.41  |
| Oral antidiabetics       | 34 (27.0%)     | 21 (25.3%)                   | 13 (30.2%)                           | 0.55  |
| ACE inhibitor/ARB        | 71 (56.3%)     | 43 (51.8%)                   | 28 (65.1%)                           | 0.15  |
| Antropometric and laboratory parameters* |            |                              |                                      |       |
| BMI (Kg/m\textsuperscript{2}) | 28.9 ± 4.6     | 29.2 ± 3.8                   | 30.3 ± 5.6                           | 0.02  |
| Total cholesterol (mg/dl) | 175.6 ± 43.1   | 172.7 ± 40.7                 | 181.0 ± 47.2                         | 0.31  |
| LDL (mg/dl)              | 101.1 ± 36.0   | 101.6 ± 36.6                 | 100.1 ± 35.6                         | 0.21  |
| HDL (mg/dl)              | 47.5 ± 12.3    | 46.6 ± 11.2                  | 49.3 ± 13.5                          | 0.26  |
| Triglycerides (mg/dl)    | 130.9 ± 53.5   | 121.1 ± 42.1                 | 149.7 ± 67.1                         | 0.01  |
| Glomerular filtration (mL/min/1.73 m\textsuperscript{2}) | 74.6 ± 20.3   | 80.1 ± 15.2                 | 63.4 ± 24.6                          | <0.01 |
| SPECT data               |                |                              |                                      |       |
| Indication               |                |                              |                                      |       |
| Diagnostic               | 57 (45.2%)     | 37 (44.6%)                   | 20 (46.5%)                           | 0.84  |
| Pronotic                 | 69 (54.8%)     | 46 (55.4%)                   | 23 (53.5%)                           |       |
| METS                     | 8.1 ± 2.0      | 8.1 ± 2.0                    | –                                     |       |
| Initial BP               | 138.1 ± 21.2   | 135.1 ± 18.6                 | 143.8 ± 27.7                         | 0.05  |
| Maximum intensity BP     | 157.9 ± 31.7   | 167.5 ± 31.9                 | 139.2 ± 21.6                         | <0.01 |
| Basal HR                 | 71.2 ± 15.3    | 71.3 ± 15.8                  | 71.1 ± 14.4                          | 0.95  |
| Maximal HR               | 114.8 ± 26.5   | 127.8 ± 20.5                 | 89.8 ± 14.4                          | <0.01 |
| % Increase HR            | 65.9 ± 44.9    | 85.4 ± 41.6                  | 28.1 ± 20.1                          | <0.01 |
| FE                       | 55.9 ± 11.8    | 55.0 ± 11.2                  | 57.5 ± 12.9                          | 0.28  |
| Positive test for Ischemia | 59 (46.8%)     | 39 (47.0%)                   | 20 (46.5%)                           | 0.95  |

Table 1. Epidemiologic and demographic characteristics of the patients included in the study. *Mean ± SD.
Figure 1. Typical serum spectra obtained from one patient using different pulse sequences. (A) pulse-and-acquire, (B) CPMG with an effective T2 delay of 32 ms and (C) diffusion edited spectra. Only the aliphatic part of the spectra is shown, spectra were acquired as described in the methods section. Tentative assignations based on chemical shift are as follows: (a) and (b) methyl end methylene groups of fatty acid chains in lipoproteins respectively; (c) Valine, leucine and isoleucine; (d) lactate; (e) alanine; (f) protons next to double bonds in fatty acid chains; (g) glutamate; (h) trimethylamine containing compounds and (i) glucose.

Table 2. Characteristics of the OPLS-DA models obtained to differentiate between sexes.

| Sequence   | RX   | RY   | Q²   | Fisher  | CV ANOVA |
|------------|------|------|------|---------|----------|
| WG         | 0.77 | 0.49 | 0.30 | 1.4−11 | 1.5−11   |
| CPMG       | 0.67 | 0.58 | 0.44 | 1.10−16 | 1.13−16  |
| Diffusion  | 0.60 | 0.31 | 0.25 | 2.0−15 | 2.16−14  |
| NOESYPR1D  | 0.55 | 0.15 | 0.09 | 1.0−3  | 4.04−3   |
The effect of stress test. Visual inspection of the spectra showed that exercise stress testing induced an increase in the lactate peak at around 1.35 ppm that returned to pre-test values after the test concluded, an increase that was not detected in the case of pharmacological stress. As shown in Fig. 3, a clear clustering in the exercise stress samples could be observed between pre-test and the time of maximum effort in OPLS-DA (Fig. 3A). However it was not possible to differentiate between pre-test and time of maximum effort in pharmacological stress. Furthermore, pharmacological samples obtained at the time of maximum effort tended to cluster with the pre-test exercise samples suggesting that no metabolic changes had happened during the test. Quantification of the metabolites confirmed that discrimination between pre-test and maximum effort relied on an increase in lactate and alanine (Fig. 3B,C) in exercise but not in pharmacological stress (Supplementary Table 3). There were no changes in the other metabolites quantified. These results confirm that the metabolic effects induced by exercise and pharmacological stress are markedly different, with potential consequences on the induction and interpretation of ischemia in patients undergoing pharmacological stress test.
Prediction of stress test result. Among all patients undergoing pharmacological test, 20 had a positive result. Twenty-three matched controls were selected for comparisons. Similarly, 39 patients undergoing exercise stress test had a positive result, for which 44 matched controls were selected. Characteristics of patients in all groups are presented in Table 4. Cases and controls were similar with regards to demographics and past medical history, except for the presence of prior ischemic heart disease, which was higher in cases than in controls both in the exercise ($P = 0.03$) and the pharmacological stress test groups ($P < 0.01$).

Using the samples obtained before the stress test, we created several models in order to evaluate the role of the metabolic profile in the prediction of the stress test results (positive or negative for ischemia). Models made with spectra that contained lipids were statistically significant according to Fisher’s exact test but only the one made with diffusion spectra had a $P < 0.05$ according to CV-ANOVA, and a classification success of 70% (Fig. 4).

### Table 4. Serum metabolite concentration (mmol/L) according to the type of exercise; measured before and at the time of maximum intensity. $P$ values were corrected for multiple comparisons.

| Metabolite       | Exercise Before | Maximum intensity | $p$ | Pharmacological Before | Maximum intensity | $p$ |
|------------------|-----------------|-------------------|-----|------------------------|-------------------|-----|
| 3-Hydroxybutyrate| 0.044 ± 0.027   | 0.039 ± 0.025     | 0.591| 0.043 ± 0.021          | 0.044 ± 0.023     | 0.994 |
| Acetate          | 0.021 ± 0.014   | 0.022 ± 0.016     | 0.898| 0.027 ± 0.013          | 0.094 ± 0.406     | 0.994 |
| Alanine          | 0.008 ± 0.004   | 0.011 ± 0.006     | 0.0006| 0.009 ± 0.005          | 0.009 ± 0.004     | 0.994 |
| Betaine          | 0.021 ± 0.015   | 0.021 ± 0.015     | 0.898| 0.024 ± 0.021          | 0.026 ± 0.020     | 0.994 |
| Creatine         | 0.014 ± 0.010   | 0.014 ± 0.010     | 0.898| 0.014 ± 0.008          | 0.016 ± 0.013     | 0.994 |
| Creatinine       | 0.027 ± 0.016   | 0.027 ± 0.016     | 0.898| 0.042 ± 0.035          | 0.042 ± 0.035     | 0.994 |
| Glucose          | 1.725 ± 1.048   | 1.608 ± 1.028     | 0.898| 1.980 ± 0.970          | 1.982 ± 0.980     | 0.994 |
| Glycine          | 0.019 ± 0.029   | 0.013 ± 0.018     | 0.448| 0.020 ± 0.021          | 0.020 ± 0.011     | 0.994 |
| Isoleucine       | 0.063 ± 0.037   | 0.062 ± 0.037     | 0.898| 0.069 ± 0.032          | 0.072 ± 0.041     | 0.994 |
| Lactate          | 0.934 ± 0.548   | 1.599 ± 0.970     | $2.3 \times 10^{-6}$ | 1.082 ± 0.488 | 1.025 ± 0.461 | 0.994 |
| Threonine        | 0.135 ± 0.085   | 0.145 ± 0.088     | 0.898| 0.163 ± 0.075          | 0.164 ± 0.096     | 0.994 |
| Valine           | 0.103 ± 0.062   | 0.099 ± 0.067     | 0.898| 0.105 ± 0.051          | 0.109 ± 0.060     | 0.994 |

Figure 4. Pattern recognition results from the diffusion-edited spectra for the prediction of stress test results, (A) score plot corresponding to the OPLS-DA model able to predict the result of the stress test. (B) Corresponds to the permutation analysis, (C) is the misclassification table showing Fisher’s test and (D) the ROC Curve of the model shown in (A).
The metabolic profile changed during stress, mainly in patients undergoing exercise stress test (see earlier), we evaluated the predictive ability of the metabolic profile by separating the two modalities of stress test. Interestingly it was possible to predict the result of stress test for pharmacological and exercise tests (P CV-ANOVA 0.014 and 0.033 respectively).

Finally, because exercise stress induced an increase in lactate concentrations we evaluated if lactate behaved differently between positive and negative stress. Figure 5 shows serum lactate levels and their evolution during stress test for pharmacological and exercise patients. As shown above there is a large increase in lactate levels associated to exercise. It is also worth noting a clear increase in lactate associated positive but not negative cases of pharmacological testing.

The increase in lactate seen in pharmacological positive patients (25%) is lower than the increase associate to exercise (40%); thus it is likely that myocardial lactate is not detected in the global population of exercise patients as it may be diluted by the much larger effect of exercise. Also, in preliminary experiments using a large animal model (swine) we have seen an increase in peripheral blood lactate associated to myocardial infarction (Supplementary Fig. 2) demonstrating that the metabolic effects of myocardial ischemia are detectable in the bloodstream.

Discussion

In the present work we have characterized a population that included patients with suspected CAD undergoing myocardial perfusion SPECT with physical or pharmacological stress test. The clinical and epidemiological features of the population under study are not different from other studies done in a similar environment.13,14,16,17

Of the confounding variables studied only sex and statin treatment did have an effect on the serum metabolic profile. Sex does affect the shape of the lipid peaks in the spectrum which is consistent with men and women having different lipoprotein profiles.11 It has been described that women have smaller-sized VLDL and larger sized LDL and HDL than men leading to a less atherogenic profile.18 However, sex differences are not limited to lipoproteins as they extend to some of the small metabolites present in serum as we have described in a preliminary report.19 Among the low molecular weight metabolites, glycine concentration was found to be higher in women than men. Glycine has been shown to be protective against ischemia–reperfusion injury, and has been suggested to be involved in the protective effects of remote ischemic conditioning.21 These findings might explain, at least in part, the fact that women have smaller infarct size once corrected for confounding factors.22

Statins are drugs that reduce the cholesterol levels and are able to reduce cardiovascular risk.23 The effect of statin treatment on the metabolic profile could be detected only in diffusion-edited and pulse-and-acquire spectra that contain the full lipoprotein envelope. The main differences were found at 1.28 and at around 2.0 ppm, the area were lipid double bonds appear. Changes in the 1.28 ppm had previously been reported and our findings regarding the double bonds are in accordance with previous findings that statins change lipid composition but not circulating amino acids, ketones, or glycolysis-related metabolites.24

Other risk factors evaluated in population screening such as diabetes dyslipidemia or age did not affect the metabolic profile in the cohort under study. Numerous metabolomics studies involving diabetic patients and diabetic cardiomyopathy have shown differences associated to the disease. In our study, one third of the patients included were diagnosed as diabetics; however, they were treated with insulin or oral antidiabetic agents and none had glucose levels above 6 mmol/L at the time of analysis suggesting that the disease was under control which could explain the lack of metabolic effect associated to diabetes.

Likewise, none of the spectra showed a clear dyslipidemic pattern although 84.8% of patients had been previously diagnosed of dyslipidemia, a similar percentage to other studies.13,15,28 Most of the patients diagnosed as
dyslipidemias in our study were treated with statins as the drugs of first choice recommended for patients with hypercholesterolemia or combined hyperlipidemia. Age has also been described as a factor affecting the metabolic profile but it was not a relevant factor modifying the metabolic pattern in our study. Furthermore, although patients performing pharmacological stress test were older than exercise stress patients, it was not possible to obtain a discriminant model to differentiate them nor could we detect age based differences. These apparent discrepancies may be explained by the lack of young patients in our study population.

Physical stress induced the accumulation of lactate and alanine in the serum, in agreement with previous studies done with mass spectrometry. On the other hand, pharmacological testing did not induce changes in the metabolic profile. Furthermore, samples taken at the time of maximum intensity of pharmacological stress test group tended to cluster with the samples taken before exercise stress test. This is in accordance with pharmacological stress test actually detecting myocardial unbalanced blood redistribution in the presence of stenosis. In view of those results, we urge caution in the interpretation of pharmacological stress testing results as the use of vasodilators does not fully mimic the regional ischemic effect seen in exercise testing.

The value of NMR spectroscopy-based metabolic profiling to predict the occurrence of exercise-induced myocardial ischemia in patients with CAD was previously evaluated by our research group using a permutation approach. Although in the present study, we have been able to obtain models to predict the occurrence of ischemia in our population and similarly to previously published results these models are statistically significant when evaluated using Q2 or Fisher’s probability test that has been proposed as a better model for biomarker discovery. However, only diffusion edited spectra was able to reach statistical significance when the models were evaluated with CV-ANOVA, a more restrictive statistical approach. In view of these results, a new study with increased number of patients (and power) should be performed.

It is interesting to note that in the case of pharmacological stress testing we could detect an increase in lactate associated to positive stress results. We hypothesize that this lactate originates in the heart; an idea supported by the fact that in a large animal model we are able to detect an increase in lactate in peripheral blood associated to myocardial infarction. In the case of physical stress testing, myocardial lactate increase would be masked due to the fact that exercise does induce a large increase in lactate most likely of muscular origin. The presence of myocardial lactate would suggest that pharmacological testing does induce ischemia, not only blood supply redistribution.

The results presented in this work showed a 70% sensitivity in the detection of myocardial ischemia using a metabolomic approach. These results are similar to previous findings that tried to predict the occurrence of death after myocardial infarction. However, metabolic profile provided added value on top of other classical risk stratification approaches such as the GRACE score.

Finally, we are aware that stress testing and clinical evaluation of the patients will be the technique of choice for the prediction of ischemia in the foreseeable future. However, any approach that could reduce the burden placed on health systems would be very welcome in this role if, for example, a strategy with high negative predicting value could be devised or if it could be applied with high sensitivity to a defined population such as younger patients with reduced comorbidities.

In conclusion, we have been able to characterize the metabolic profile of patients at risk of cardiovascular events. We have established that pharmacological stress test does not reproduce the dynamic changes observed in exercise stress but it is very likely able to induce myocardial ischemia; however, care should be taken when evaluating clinical results. Finally, although there is promising evidence suggesting that 1H NMR based metabolomics could predict stress test results this study was underpowered to obtain a definitive answer.

**Experimental Patients and study design.** The study was prospectively conducted in 244 consecutive patients with suspected cardiovascular risk who were referred at Hospital Vall d’Hebron to perform a myocardial perfusion SPECT study either with exercise stress testing on a treadmill (Bruce protocol), or with pharmacological stress with dipyridamole or regadenoson. Patients had to be older than 18 year old, and were included in the Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT (METS- Clinicaltrial.gov identifier: NCT0298771) study. Patients unable to sign the written consent, pregnant women and patients with dobutamine indication in the stress protocol were excluded.

The study embraced four groups of patients. Patients were divided into two groups depending on the type of stress test to which they were subjected (exercise or pharmacological). Within each group, two subgroups were defined according to the result reported by the SPECT: cases were patients whose result was positive for myocardial ischemia and controls were those with negative result. All cases were included in the study, whereas age and sex-matched controls were selected for both exercise and pharmacological groups.

The study was approved by the Hospital Vall d’Hebron’s ethics committee, all patients gave their written informed consent to be included and all methods were performed in accordance with the relevant guidelines. Patients were interviewed, their clinical records examined, and information on their medical history retrieved from medical records.

**Samples.** Fasted venous blood samples (5 ml) were obtained before stress test, at the time of maximum intensity and after the test for each patient using the same intravenous line used for radiopharmaceutical and coronary vasodilator in the case of pharmacological stress test. Blood was allowed to clot for two hours at room temperature, then, the serum was collected by centrifugation at 1000 g, 4 °C, for 5 min and stored at − 80 °C until assayed.
**Serum deproteinization.** Serum deproteinization was done using methanol precipitation according to protocols described previously. Briefly, 200 μl of serum were mixed with 400 μl of methanol, vortexed, and kept at –20 °C for 20 min. Afterwards, the mixtures were centrifuged at 11,000g, 4 °C, for 30 min. The supernatants were recovered, dried under a stream of nitrogen and stored at –80 °C until NMR analysis.

**NMR spectroscopy.** For whole serum samples, 200 μl of serum were diluted with 300 μl of phosphate-buffered saline (PBS) at pH 7.4 prepared with D2O and placed in 5 mm NMR tubes for analysis. A series of spectra including: (1) pulse-acquire sequence preceded with WATERGATE 3–9–19, (2) a CPMG with an effective T2 delay of 32 ms, and (3) diffusion edited spectra were acquired for each sample. CPMG and diffusion edited sequences were preceded by presaturation of the water signal for 2 s. Each spectrum consisted in the accumulation of 64 scans and lasted approximately 5 min.

In the case of deproteinized serum, dried samples were reconstituted in 500 μl of PBS made up with D2O, containing 0.5 mM trimethylsilyl tetradeuteropropionic acid sodium salt (TSP) as an internal standard at a final concentration 0.5 mM. Each spectrum consisted in the accumulation of 64 scans with NOESYPR1D pulse sequence with a mixing time of 100 ms. Spectra were obtained at 300 K on a 400 MHz vertical bore magnet interfaced to a Bruker Avance console.

**Pattern recognition.** Prior to pattern recognition each spectrum was manually phase corrected, normalized to a total area of 1 and variables pareto scaled. The area between 0.5 and 9 ppm (excluding the water zone) were divided into bins of equal width of 0.01 ppm and imported in SIMCA (Umetrics, Umea, Sweden) software version 14.0 for further analysis. A non-supervised classification approach such as Principal Component Analysis (PCA) was used. When PCA was not able to cluster the samples, Orthogonal Projection to Latent Structures Discriminant Analysis (OPLS-DA), a supervised analysis, approach was used. Discriminant models were considered statistically significant if CV-ANOVA was < 0.05.

Metabolite quantification was performed in spectra of desproteinized samples using Chenomx software (Chenomx, Inc. Edmonton, AB, Canada) by comparing de areas of the peaks of interest to that of TSP added as an internal standard at a final concentration of 0.5 mM.

**Statistical analysis.** Demographic and clinical data processing was carried out using statistical package SPSS version 21.0. Categorical variables were summarized by absolute and relative frequencies. The Kolmogorov–Smirnov test confirmed the normal distribution of all continuous variables collected in the study, which were reported as mean ± standard deviation (SD). Categorical variables were compared with the χ² test. Continuous variables were compared with the Student t test. P value was considered statistically significant when was <0.05. P values were corrected for multiple comparisons when appropriate.

Received: 31 May 2020; Accepted: 7 October 2020
Published online: 20 October 2020

References

1. Ezzati, M. et al. The contributions of risk factor trends and medical care to cardiovascular mortality trends. Nat. Rev. Cardiol. 12, 508–530 (2015).
2. Montalescot, G. et al. Guidelines on the management of stable coronary artery disease. Eur. Heart J. 34, 2949–3003 (2013).
3. Greenland, P. & Gaziano, J. M. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N. Engl. J. Med. 349, 465–473 (2003).
4. Berger, J. S., Jordan, C. O., Lloyd-Jones, D. & Blumenthal, R. S. Screening for cardiovascular risk in asymptomatic patients. J. Am. Coll. Cardiol. 55, 1169–1177 (2010).
5. Miller, D. D. & Shaw, L. J. Coronary artery disease: diagnostic and prognostic models for reducing patient risk. J. Cardiovasc. Nurs. 21, 52–16 (2006).
6. Danad, I. et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur. Heart J. 38, 991–998 (2017).
7. Goff, D. C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 63, 2935–2959 (2014).
8. Rasmiena, A. A. A., Ng, T. W. W. & Meikle, P. J. J. Metabolomics and ischaemic heart disease. Clin. Sci. 124, 289–306 (2012).
9. Nicholson, J. K. et al. Metabolic phenotyping in clinical and surgical environments. Nature 491, 384–392 (2012).
10. Brindle, J. T. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8, 1439–1445 (2002).
11. Kirschloren, H. L. et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med. 12, 705–710 (2006).
12. Barba, I., Andres, M. & Garcia-Dorado, D. Metabolomics and heart diseases: from basic to clinical approach. Curr. Med. Chem. 26, 46–59 (2019).
13. Sabatine, M. S. et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868–3875 (2005).
14. Barba, I. et al. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Reson. Med. 60, 27–32 (2008).
15. Limkakeng, A. T. et al. Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing. PLoS ONE 14, e0211762 (2019).
16. Kochhar, S. et al. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal. Biochem. 352, 274–281 (2006).
17. Romero-Farina, G., Candell-Riera, J., Agudé-Bruix, S., Pizzi, M. N. & Garcia-Dorado, D. Different prognosis according to different clinical, electrocardiographic and scintigraphic ischemia criteria. Int. J. Cardiol. 219, 240–246 (2016).
18. Freedman, D. S. et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham study. Clin. Chem. 50, 1189–1200 (2004).
19. Barba, I., Andréis, M., Picón, I., Aguade-Bruix, S. & García-Dorado, D. Sex differences in the 1H NMR metabolic profile of serum in cardiovascular risk patients. Sci. Rep. 9, 2380 (2019).
20. Ruiz-Meana, M. et al. Glycine protects cardiomyocytes against lethal reoxygenation injury by inhibiting mitochondrial permeability transition. J. Physiol. 558, 873–882 (2004).
21. Alburquerque-Béjar, J. J. et al. Remote ischemic conditioning provides humoral cross-species cardioprotection through glycine receptor activation. Cardiovasc. Res. 113, 52–60 (2017).
22. De Luca, G. et al. Relation of gender to infarct size in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Am. J. Cardiol. 111, 936–940 (2013).
23. Collins, R. et al. MRC/BHF Heart Protection Study of cholesterol lowering simvastatin in 5963 people with diabetes: a randomized controlled trial. Heart Protection Study Collaborative Group. Lancet 361, 2005–2016 (2003).
24. Würtz, P. et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J. Am. Coll. Cardiol. 67, 1200–1210 (2016).
25. Mäkinen, V.-P. et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 4, 167 (2008).
26. Friedrich, N. Metabolomics in diabetes research. J. Endocrinol. 215, 29–42 (2012).
27. Sowton, A. P., Griffin, J. L. & Murray, A. J. Metabolic profiling of the diabetic heart: toward a richer picture. Front. Physiol. 10, 639 (2019).
28. Shah, S. H. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 3, 207–214 (2010).
29. Peppeoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 37, 2315–2381 (2016).
30. Rist, M. J. et al. Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. PLoS ONE 12(8), e0183228 (2017).
31. Saito, K. et al. Gender- and age-associated differences in serum metabolite profiles among japanese populations. Biol. Pharm. Bull. 39, 1179–1186 (2016).
32. Travin, M. I. & Weizler, J. P. Pharmacological stress testing. Semin. Nuclear Med. 29, 298–318 (1999).
33. Szymanska, E., Saccani, E., Smilde, A. K. & Westerhuis, J. A. Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies. Metabolomics 8, 3–19 (2012).
34. Eriksson, L., Trygg, J. & Wold, S. CV-ANOV A for significance testing of PLS and OPLS models in metabolomics studies. J. Chemom. 22, 594–600 (2008).
35. Vignoli, A. et al. NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort. BMC Med. 17, 1–13 (2019).
36. Gowda, N. G. A. & Raftery, D. Quantitating metabolites in protein precipitated serum using NMR spectroscopy. Anal. Chem. 86, 5433–5440 (2014).

Acknowledgements
This work was supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (Grants PI14/01431 and PI17/01397, SGR-1807, CIBER-CV and CIBERESP), co-financed by the European Regional Development Fund (ERDF-FEDER, a way to build Europe).

Author’s Contributions
C.L. and M.C. acquired and processed the data. M.A. performed stress test and evaluated patient data. S.A. and I.B. performed data analysis and interpretation. C.L., M.C., M.A., S.A., I.F.-G. and I.B. wrote the manuscript. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-74880-6.

Correspondence and requests for materials should be addressed to I.F.-G. or I.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020